Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Fiera Capital Corp

Fiera Capital Corp cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 348,212 shares of the biotechnology company's stock after selling 8,111 shares during the quarter. Fiera Capital Corp owned 0.37% of Sarepta Therapeutics worth $33,578,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of SRPT. Vanguard Capital Wealth Advisors grew its holdings in Sarepta Therapeutics by 3.8% during the fourth quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company's stock worth $236,000 after acquiring an additional 90 shares during the period. Cary Street Partners Investment Advisory LLC raised its holdings in shares of Sarepta Therapeutics by 154.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company's stock worth $31,000 after purchasing an additional 154 shares in the last quarter. Natixis Advisors L.P. raised its holdings in shares of Sarepta Therapeutics by 0.6% in the 3rd quarter. Natixis Advisors L.P. now owns 26,026 shares of the biotechnology company's stock worth $3,155,000 after purchasing an additional 160 shares in the last quarter. New York Life Investment Management LLC boosted its holdings in Sarepta Therapeutics by 1.7% during the fourth quarter. New York Life Investment Management LLC now owns 9,942 shares of the biotechnology company's stock worth $959,000 after buying an additional 166 shares in the last quarter. Finally, LGL Partners LLC boosted its holdings in Sarepta Therapeutics by 4.6% during the third quarter. LGL Partners LLC now owns 4,196 shares of the biotechnology company's stock worth $509,000 after buying an additional 186 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

Insiders Place Their Bets

In other news, insider Bilal Arif sold 2,000 shares of the firm's stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the sale, the insider now directly owns 26,836 shares of the company's stock, valued at $3,457,550.24. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Dallan Murray sold 3,635 shares of the business's stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the transaction, the insider now directly owns 18,125 shares in the company, valued at $2,537,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Bilal Arif sold 2,000 shares of the company's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the transaction, the insider now owns 26,836 shares of the company's stock, valued at $3,457,550.24. The disclosure for this sale can be found here. Insiders sold 25,731 shares of company stock valued at $3,248,319 over the last 90 days. 7.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

SRPT has been the subject of a number of recent research reports. Oppenheimer upgraded Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and set a $180.00 price objective for the company in a research report on Tuesday. Wedbush reiterated an "outperform" rating and issued a $224.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Royal Bank of Canada upped their price objective on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the company an "outperform" rating in a research note on Thursday, February 29th. Barclays lifted their target price on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an "overweight" rating in a research report on Thursday, February 29th. Finally, UBS Group upped their price target on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a "buy" rating in a research report on Friday, March 1st. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $161.81.

Sarepta Therapeutics Stock Up 0.2 %

Shares of SRPT stock traded up $0.24 on Thursday, hitting $132.74. The company's stock had a trading volume of 1,010,025 shares, compared to its average volume of 1,027,159. The stock has a market capitalization of $12.55 billion, a price-to-earnings ratio of 1,206.73 and a beta of 0.95. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $152.21. The firm's fifty day moving average price is $126.36 and its 200-day moving average price is $112.14. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The company had revenue of $413.50 million during the quarter, compared to analysts' expectations of $375.52 million. During the same quarter in the previous year, the firm earned ($1.44) earnings per share. The business's quarterly revenue was up 63.1% compared to the same quarter last year. Research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.68 EPS for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.